Study of ARC-520 in Patient With Chronic Hepatitis B Virus

NCT ID: NCT02349126

Last Updated: 2025-12-26

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-02-28
• Study Completion Date: 2016-03-31

Brief Summary

Patients with chronic HBV infection will receive ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.

Detailed Description

This is a single-center, open-label study of ARC-520 in combination with entecavir or tenofovir administered to patients with immune active chronic HBV infection. An iterative trial design is anticipated with potential inclusion of additional cohorts with anticipated enrollment of up to 60 patients. Patients who have signed a Human Research Ethics Committee approved informed consent, and have met all of the protocol eligibility criteria will continue receiving daily oral entecavir (0.5-1.0 mg/day) or daily oral tenofovir (300 mg/day) and a single IV injection of ARC-520. If a serious adverse event (SAE) deemed possibly or probably related to study drug should occur at any point during the study, any further dosing will be put on hold pending a complete review of safety data by the sponsor and the Principal Investigator. Patients will undergo the following evaluations at regular intervals during the study: medical history, physical examinations, vital sign measurements (blood pressure, heart rate, respiratory rate, and temperature), weight, AEs, 12-lead ECGs, concomitant medication, blood sample collection for hematology, coagulation, chemistry, PK and exploratory PD measures, HBV virology. Patients will be monitored for a total of 12 weeks. Clinically significant changes including AEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the patient is lost to follow-up.

Conditions

Chronic Hepatitis B

Keywords

Hepatitis B; HBV infection; Hepatitis B Surface Antigen

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment Group

ARC-520 Injection

Group Type: EXPERIMENTAL

ARC-520 Injection

Intervention Type: DRUG

ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.

Interventions

ARC-520 Injection

ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.

Intervention Type: DRUG

Other Intervention Names

ARC-520

Eligibility Criteria

Inclusion Criteria

• Male or female, 18 to 65 years of age
• Written informed consent
• No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment
• No abnormal finding of clinical relevance
• Diagnosis of immune active chronic HBV infection
• > 6 months of continuous treatment with daily, oral entecavir or tenofovir

Exclusion Criteria

• Pregnant or lactating
• Acute signs of hepatitis/other infection within 4 weeks of screening
• Antiviral therapy other than entecavir or tenofovir within 3 months of screening
• Prior treatment with interferon or a toll receptor agonist in last 12 months
• Use of anticoagulants, corticosteroids, immunomodulators, or immunosuppressants
• Use of dietary and/or herbal supplements that can interfere with liver metabolism
• Use of any drugs known to induce or inhibit hepatic drug metabolism
• Use of prescription medication or over-the-counter products
• Depot injection/implant of any drug except birth control.
• Known diagnosis of diabetes mellitus.
• History of autoimmune disease
• Human immunodeficiency virus (HIV) infection
• Sero-positive for HCV, and/or history of delta virus hepatitis
• Hypertension: blood pressure > 150/100 mmHg
• History of cardiac rhythm disturbances
• Family history of congenital long QT syndrome/unexplained sudden cardiac death
• Symptomatic heart failure, unstable angina, myocardial infarction, severe cardiovascular disease
• History of malignancy, except adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, in situ cervical cancer
• Major surgery within 3 months of screening
• History of alcohol and/or drug abuse < 12 months from screening
• Regularly uses alcohol within past 6 months (ie, more than 14 units of alcohol per week)
• Evidence of acute inflammation, sepsis, or hemolysis
• Diagnosed with a significant psychiatric disorder
• Use of drugs of abuse
• History of allergy to bee venom
• Use of investigational agents/devices within 30 days
• Current participation in an investigational study
• Clinically significant gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease
• History/presence of Gilbert's syndrome, conditions that interfere with absorption, distribution, metabolism, excretion of drugs
• Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction
• Clinically significant history/presence of uncontrolled systemic disease
• Donated blood (500 mL) within 7 days prior to study treatment administration
• History of fever within 2 weeks of screening
• Immunization/planned immunization with live attenuated vaccine except influenza vaccine
• Excessive exercise/physical activity within 7 days of screening/enrolment or during study
• History of coagulopathy or stroke within past 6 months, and/or concurrent anticoagulants

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Arrowhead Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Research Site 1

Melbourne, Victoria, Australia

Countries

Australia

Other Identifiers

Heparc-2005

Identifier Type: -

Identifier Source: org_study_id